Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

Author(s): N. Geis, S. Zell, R. Rutz, W. Li, T. Giese, S. Mamidi, S. Schultz, M. Kirschfink.

Abstract:

The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is limited by over-expression of one or more membrane-bound complement regulatory proteins (mCRPs: CD46, CD55, CD59) on the surface of neoplastic cells. In this study we designed small interfering RNAs (siRNAs) for posttranscriptional gene knock down of CD46, CD55 and CD59 aiming to sensitize tumor cells to complement attack and thereby to better exploit complement for tumor cell destruction. Tumor cell lines of different origin, such as Du145 (prostate), BT474 (breast) and K562 (erythroleukemia) were selected for the study. FACS-analysis demonstrated that siRNA anti-CD46(301) reduced CD46 protein expression up to 80%, siRNA anti-CD55(255) diminished CD55 protein expression up to 49%, and CD59 protein expression was inhibited up to 82% by siRNA anti-CD59(1339). Time course experiments revealed a long-lasting silencing effect with > 50% complement regulator inhibition up to day 13. Upon mCRP knock down, complementdependent cytotoxicity (CDC) was augmented by 20-30% for CD46, by up to 24% for CD55 and by up to 55% for CD59. The combined inhibition of all three inhibitors further enhanced CDC by up to 66%. Dependent on the cell line, CD46 and CD55 downregulation increased significantly C3 ospsonization, which is known to support cell-mediated defense mechanisms. mCRP blocking antibodies were only partly able to further augment the tumor cells susceptibility to complement lysis. Thus, siRNA-induced inhibition of complement regulator expression clearly sensitizes malignant cells to complement attack and, if specifically targeted to the tumor, appears suited as adjuvant to improve antibody-based cancer immunotherapy.

Keywords: Complement-dependent cytotoxicity, complement resistance, immunotherapy, membrane complement regulatory proteins, siRNA, tumor immunology, siRNA Sensitizes Tumor Cells, Prostaglandin, anaphylatoxins, DU145 prostate carcinoma cells, Karlsruhe, Germany, random siRNA, Oligofectamine, Cytometry, IBGRL, QIFIKIT, Europium solution, MagnaPure-LC, LightCycler, mRNA, Downregulation, carcinoma cells, enhance C3 opsonization, Monoclonal antibodies, immune stimulation, cytoplasmic siRNA, immortalized breast cell, bulky lymphoma, paroxysmal nocturnal hemoglobinuria, CDC, RT-PCR

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 10
ISSUE: 8
Year: 2010
Page: [922 - 931]
Pages: 10
DOI: 10.2174/156800910793357952
Price: $58